Loading company…
Sheng Wei Kun Teng develops molecular point-of-care diagnostic devices and tests.
Sheng Wei Kun Teng develops and sells medical devices and analytical instruments, including the Q-POC™ molecular diagnostic platform for infectious disease testing, drug resistance screening, genetic testing, and early cancer screening. Based in Changsha, China, it has a UK subsidiary, QuantuMDx Group Ltd., and its product has EU CE certification. In December 2024, it raised approximately CNY 200 million in Series A funding from Sansure Biotech Inc., Voyagers Capital, and Rongquan Venture Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in